Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Early Detection of Cancer | 3 | 2024 | 362 | 0.380 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 237 | 0.350 |
Why?
|
| Papillomavirus Infections | 2 | 2024 | 296 | 0.280 |
Why?
|
| Prostate-Specific Antigen | 2 | 2018 | 255 | 0.240 |
Why?
|
| Hydrogen Sulfide | 1 | 2024 | 12 | 0.230 |
Why?
|
| Varenicline | 1 | 2024 | 14 | 0.230 |
Why?
|
| Golgi Apparatus | 1 | 2024 | 93 | 0.230 |
Why?
|
| Camping | 1 | 2004 | 14 | 0.220 |
Why?
|
| Mass Screening | 4 | 2024 | 786 | 0.220 |
Why?
|
| Bayes Theorem | 1 | 2024 | 285 | 0.210 |
Why?
|
| Emergency Medical Services | 2 | 2004 | 397 | 0.200 |
Why?
|
| Smoking Cessation | 1 | 2024 | 198 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1251 | 0.200 |
Why?
|
| Papillomavirus Vaccines | 1 | 2024 | 94 | 0.200 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 2515 | 0.200 |
Why?
|
| Indazoles | 1 | 2020 | 24 | 0.180 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 558 | 0.180 |
Why?
|
| Deoxycytidine | 1 | 2020 | 78 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 121 | 0.160 |
Why?
|
| Sulfonamides | 1 | 2020 | 271 | 0.150 |
Why?
|
| Oligopeptides | 1 | 2018 | 118 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 576 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2020 | 374 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 1549 | 0.140 |
Why?
|
| Dexamethasone | 1 | 2018 | 276 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 161 | 0.130 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2018 | 165 | 0.130 |
Why?
|
| Lymphoma, Follicular | 1 | 2016 | 30 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1726 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 78 | 0.120 |
Why?
|
| Trauma, Nervous System | 1 | 2014 | 5 | 0.120 |
Why?
|
| Vertebral Artery Dissection | 1 | 2014 | 4 | 0.120 |
Why?
|
| Bone Marrow | 1 | 2016 | 325 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 144 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 135 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 192 | 0.110 |
Why?
|
| Aged | 10 | 2024 | 19896 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 292 | 0.110 |
Why?
|
| Smoking | 1 | 2018 | 1051 | 0.100 |
Why?
|
| Adult | 12 | 2024 | 29692 | 0.100 |
Why?
|
| Middle Aged | 11 | 2024 | 26990 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2018 | 837 | 0.090 |
Why?
|
| Disease Management | 1 | 2014 | 529 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 6607 | 0.080 |
Why?
|
| Young Adult | 5 | 2024 | 9069 | 0.080 |
Why?
|
| Female | 14 | 2024 | 66885 | 0.080 |
Why?
|
| Humans | 18 | 2024 | 125392 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1496 | 0.070 |
Why?
|
| Male | 11 | 2024 | 61663 | 0.060 |
Why?
|
| United Kingdom | 2 | 2018 | 191 | 0.060 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2024 | 14 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 3350 | 0.060 |
Why?
|
| Michigan | 1 | 2004 | 42 | 0.060 |
Why?
|
| Utilization Review | 1 | 2004 | 40 | 0.050 |
Why?
|
| Kentucky | 1 | 2023 | 28 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5185 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2024 | 254 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2004 | 345 | 0.050 |
Why?
|
| Motor Vehicles | 1 | 2002 | 9 | 0.050 |
Why?
|
| Spouse Abuse | 1 | 2002 | 16 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2024 | 472 | 0.050 |
Why?
|
| Adolescent | 5 | 2024 | 19373 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2002 | 107 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 3440 | 0.040 |
Why?
|
| Patient Admission | 1 | 2002 | 185 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1329 | 0.040 |
Why?
|
| Craniocerebral Trauma | 1 | 2002 | 139 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 680 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 315 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2002 | 346 | 0.040 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2002 | 370 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 964 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 122 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 300 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2018 | 77 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2018 | 145 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2018 | 283 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 419 | 0.030 |
Why?
|
| Social Class | 1 | 2018 | 190 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2004 | 3741 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 341 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2004 | 1070 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 6168 | 0.030 |
Why?
|
| Pandemics | 1 | 2024 | 1115 | 0.030 |
Why?
|
| Incidence | 1 | 2023 | 3154 | 0.030 |
Why?
|
| South Carolina | 1 | 2015 | 10 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 147 | 0.030 |
Why?
|
| United States | 2 | 2024 | 10936 | 0.030 |
Why?
|
| General Practitioners | 1 | 2015 | 18 | 0.030 |
Why?
|
| Mastectomy | 1 | 2015 | 64 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 723 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 236 | 0.030 |
Why?
|
| Time Factors | 1 | 2004 | 6345 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 686 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 477 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1140 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2016 | 16389 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 1020 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 512 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 1240 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2820 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 872 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2014 | 339 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2018 | 777 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1897 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2058 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2018 | 12412 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 695 | 0.020 |
Why?
|
| Child | 2 | 2014 | 24436 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 4824 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 17637 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2014 | 722 | 0.020 |
Why?
|
| Animals | 1 | 2024 | 34241 | 0.010 |
Why?
|
| Traumatology | 1 | 2002 | 24 | 0.010 |
Why?
|
| Trauma Severity Indices | 1 | 2002 | 86 | 0.010 |
Why?
|
| Injury Severity Score | 1 | 2002 | 226 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 762 | 0.010 |
Why?
|
| Women's Health | 1 | 2002 | 134 | 0.010 |
Why?
|
| Trauma Centers | 1 | 2002 | 183 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 590 | 0.010 |
Why?
|
| Physician's Role | 1 | 2002 | 168 | 0.010 |
Why?
|
| General Surgery | 1 | 2002 | 206 | 0.010 |
Why?
|
| Alcoholism | 1 | 2002 | 231 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2002 | 389 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 12518 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 14030 | 0.010 |
Why?
|
| Length of Stay | 1 | 2002 | 1312 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2002 | 764 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 2917 | 0.010 |
Why?
|
| Prevalence | 1 | 2002 | 2467 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2107 | 0.010 |
Why?
|
| Risk Factors | 1 | 2002 | 10331 | 0.000 |
Why?
|